News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Bioject Medical Technologies Inc. Q3 Loss Narrows; CEO To Retire
November 2, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BIOJECT MEDICAL TECHNOLOGIES INC. (BJCT.O: Quote, Profile, Research) The company, which makes needle-free drug delivery systems, said Chief Executive Jim O'Shea would to retire at year-end. (Reporting by Saumyadeb Chakrabarty in Bangalore)
Twitter
LinkedIn
Facebook
Email
Print
People
MORE ON THIS TOPIC
IPO
Electra lights up with $350M IPO for pivotal immune-disease drug development
September 18, 2026
·
1 min read
·
Gabrielle Masson
Deals
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
September 17, 2026
·
2 min read
·
Michael Gibney
Deals
Fed rate hike won’t hold biotech down despite climbing capital costs
September 17, 2026
·
2 min read
·
Annalee Armstrong
Neuroscience
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
September 17, 2026
·
2 min read
·
Tristan Manalac
